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Abstract
Objective: The main goal of our study was to assess the 
impact of vascular procedures on the activity of hemostatic and 
fibrinolytic pathways.
Methods: We enrolled 38 patients with ≥ 45 years old undergoing 
surgery for abdominal aortic aneurysm or peripheral artery disease 
under general or regional anesthesia and who were hospitalized 
at least one night after the procedure. Patients undergoing carotid 
artery surgery and those who had acute bypass graft thrombosis, 
cancer, renal failure defined as estimated glomerular filtration 
rate < 30 ml/min/1.73m2, venous thromboembolism three months 
prior to surgery, or acute infection were excluded from the study. 
We measured levels of markers of hemostasis (factor VIII, von 
Willebrand factor:ristocetin cofactor [vWF:CoR], antithrombin), 
fibrinolysis (D-dimer, tissue plasminogen activator [tPA], plasmin-
antiplasmin complexes), and soluble cluster of differentiation 40 
ligand (sCD40L) before and 6-12h after vascular procedure.
Results: Significant differences between preoperative and 
postoperative levels of factor VIII (158.0 vs. 103.3, P<0.001), 
antithrombin (92.1 vs. 74.8, P<0.001), D-dimer (938.0 vs. 2406.0, 
P=0.005), tPA (10.1 vs. 12.8, P=0.002), and sCD40L (9092.9 vs. 
1249.6, P<0.001) were observed. There were no significant 
differences between pre- and postoperative levels of vWF:CoR 
(140.6 vs. 162.8, P=0.17) and plasmin-antiplasmin complexes 
(749.6 vs. 863.7, P=0.21).
Conclusion: Vascular surgery leads to significant alterations 
in hemostatic and fibrinolytic systems. However, the direction of 
these changes in both pathways remains unclear and seems to 
be different depending on the type of surgery. A study utilizing 
dynamic methods of coagulation and fibrinolysis assessment 
performed on a larger population is warranted.
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Abbreviations, acronyms & symbols
AAA
Ag
APTEM, EXTEM, FIBTEM, 
INTEM, and HEPTEM
BMI
CAT
CD40L
CoR
ELISA
FVIII
IQR
MI
 = Abdominal aortic aneurysm
 = Antigen 
 = Types of ROTEM tests
 = Body mass index
 = Calibrated automated thrombography
 = Cluster of differentiation 40 ligand
 = Ristocetin cofactor
 = Enzyme-linked immunosorbent assay
 = Factor VIII
 = Interquartile range
 = Myocardial infarction
MINS
PAD
PAP
ROTEM
sCD40L
SD
TIA
tPA
USA
VTE
vWF
 = Myocardial injury after noncardiac surgery
 = Peripheral artery disease
 = Plasmin-antiplasmin complexes
 = Rotational thromboelastometry
 = Soluble cluster of differentiation 40 ligand
 = Standard deviation
 = Transient ischemic attack
 = Tissue plasminogen activator
 = United States of America
 = Venous thromboembolism 
 = von Willebrand factor
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Inclusion criteria in our study were: age ≥ 45 years, general or 
regional anesthesia for vascular surgery, and at least one-night 
hospital stay after the procedure. Exclusion criteria in this study 
were: carotid artery surgery, acute bypass graft thrombosis, 
cancer, renal failure defined as estimated glomerular filtration rate 
< 30 ml/min/1,73 m2, VTE within three months before surgery, 
and acute infection. Patients using heparin, oral anticoagulants, 
or antiplatelet drugs were included in the study.
Hemostatic, fibrinolytic, and inflammatory markers were 
measured before and 6-12 hours after the procedure using the 
following methods:
1) D-dimer – turbidimetric method (Innovance D-Dimer, 
Siemens, Marburg, Germany);
2) tPA – enzyme-linked immunosorbent assay (ELISA) 
method (Zymutest t-PA Antigen, Hyphen BioMed, 
Andresy, France);
3) Antithrombin activity – chromogenic method using BCS 
analyzer (Innovance Antithrombin, Siemens, Marburg, 
Germany);
4) sCD40L – ELISA method (CD40 Quantikine ELISA Kit, R&D, 
Abingdon, United Kingdom);
5) PAP complexes – ELISA method (Technozym PAP Complex, 
Technoclone, Vienna, Austria);
6) vWF activity – turbidimetric method (BC von Willebrand 
Reagent, Siemens, Marburg, Germany);
7) Activity of FVIII – one-stage clotting assay (Siemens, 
Marburg, Germany).
All markers were measured in platelet-poor plasma.
The study was approved by the local ethics committee 
(Jagiellonian University Ethics Committee; approval number 
KBET/74/B/2010). The protocol complied with the Helsinki 
Declaration. All subjects studied signed written informed 
consent to participate.
Categorical variables were presented as numbers 
(percentages), whereas continuous variables were reported as 
medians (25-75 interquartile range), if not specified otherwise.
Preoperative and postoperative markers’ levels were 
compared using Wilcoxon signed-rank test. A P value of less than 
0.05 was considered statistically significant.
We performed a comparison of pre- and postoperative levels 
of coagulation and fibrinolysis markers in the entire cohort as 
well as separately in groups depending on the type of surgery. 
Additionally, we compared pre- and postoperative antithrombin 
activity between patients who received and those who did not 
receive heparin within seven days prior to surgery.
A statistical analysis was performed with the use of Statistica 
12 software (StatStoft®, Tulsa, Oklahoma, United States of America 
[USA]). Graphs were created in GraphPad Prism 7 software 
(GraphPad Software®, San Diego, California, USA).
RESULTS
We enrolled 38 patients with a mean age of 66.7 (standard 
deviation [SD]=7.6) years. There were 31 (81.6%) males in the 
study group. Reasons for surgery were AAA in 16 patients 
INTRODUCTION
Every year more than 200 million noncardiac surgeries are 
performed worldwide. Despite developments in perioperative 
care, 1-2% of patients die within 30 days after the procedure. 
Cardiovascular complications including myocardial injury after 
noncardiac surgery (MINS), myocardial infarction (MI), stroke, 
and venous thromboembolism (VTE) are the most common 
perioperative events influencing mortality[1,2].
MINS is defined as a prognostically relevant troponin 
elevation within 30 days after surgery, which may present with 
or without electrocardiogram changes, ischemic symptoms, 
or cardiac contractility changes. MINS is estimated to occur in 
approximately 18% of patients and it is associated with the highest 
population-attributable risk of mortality among all perioperative 
complications[3-5]. MI, which is diagnosed in 3.1-3.9% of patients 
undergoing noncardiac surgeries, is a separate clinical entity, and its 
incidence among patients undergoing high-risk vascular surgeries 
shows no temporal changes and is invariably related to poorer 
prognosis[4,6-8]. Another complication associated with noncardiac 
surgery is the perioperative stroke, that occurs in 0.05-4% of patients 
in one-year observation, depending on the type of procedure[9,10]. 
Finally, VTE is a potentially life-threatening complication associated 
with vascular surgery, which occurs in approximately 1% of patients[11].
Patients undergoing vascular surgery, who commonly present 
with pronounced atherosclerosis, seem to be at a particularly high 
risk of both venous and arterial complications due to coexistence 
of multiple comorbidities and cardiovascular risk factors[12-14]. It 
was recently reported that alterations in preoperative levels of 
coagulation and fibrinolysis markers in serum are associated with 
a higher risk of developing MINS in patients undergoing vascular 
procedures[15]. Moreover, in a study by Górka et al.[16], it was 
shown that arterial complications are more common than venous 
complications in the perioperative period and are associated with 
higher mortality. We hypothesized that a major vascular surgery 
further potentiates a prothrombotic and hypofibrinolytic state as a 
consequence of intraoperative hypotension, hypoxemia, bleeding, 
injury, and pain[17,18]. Such changes could render patients more 
susceptible to cardiovascular complications.
There is a limited number of studies concerning the influence 
of vascular surgery on hemostasis. They were performed on small 
populations and are heterogeneous in terms of markers used as well 
as the number and timing of measurements. Moreover, their results 
are ambiguous and do not produce credible conclusions. Therefore, 
in this pilot study, we aimed to assess the impact of vascular surgery 
on hemostatic (factor VIII [FVIII], von Willebrand factor [vWF] activity, 
antithrombin), fibrinolytic (D-dimer, plasmin-antiplasmin complexes 
[PAP], tissue plasminogen activator [tPA]), and inflammatory 
(soluble cluster of differentiation 40 ligand [sCD40L]) markers’ 
levels. Additionally, we assessed whether the profile of changes in 
the aforementioned systems differs between patients undergoing 
procedures for abdominal aortic aneurysm (AAA) and those treated 
surgically for peripheral artery disease (PAD).
METHODS
We enrolled 38 consecutive patients undergoing open 
vascular surgery due to PAD or AAA in the Vascular Surgery 
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DISCUSSION
Our pilot study shows that vascular procedures have a 
significant impact on hemostatic and fibrinolytic systems. 
We documented important changes between pre- and 
postoperative levels of hemostatic (FVIII, vWF:CoR, antithrombin), 
fibrinolytic (D-Dimer, tPA:Ag), and inflammatory (CD40L) markers. 
Moreover, we observed several differences in the pattern of 
perioperative alterations in the aforementioned markers’ levels 
between patients undergoing procedures for PAD and those 
treated for AAA.
Changes in coagulation markers observed in the entire 
cohort do not justify drawing definite conclusions considering 
the impact of vascular procedures on hemostasis. Firstly, we 
observed a decrease in FVIII level that is possibly secondary to 
an increase in its consumption during augmented postoperative 
hemostasis. Interestingly, some previous reports suggest 
that FVIII levels tend to increase sharply in the following days, 
thereby contributing to postoperative hypercoagulable state[19]. 
Moreover, we documented an increase in vWF levels which 
was not statistically significant and is most probably related to 
its release from endothelium in response to vascular injury[20,21]. 
Importantly, a rise of vWF level above the reference range may 
be associated with a higher risk of thrombotic complications[22].
(42.1%) and PAD in 22 patients (57.9%). Detailed clinical and 
demographic characteristics of the study group can be found in 
Table 1. In the analysis of the entire cohort we found significant 
differences between preoperative and postoperative levels of 
all markers except for vWF:ristocetin cofactor (CoR) and PAP. We 
observed a significant increase in D-dimer and tPA levels and a 
decrease in FVIII, antithrombin, and cluster of differentiation 40 
ligand (CD40L) levels. Postoperative antithrombin activity below 
the reference range of 80% was observed in 26 patients (68.4%). 
Detailed results can be found in Tables 2-4 and Figure 1.
Additionally, we performed analyses in groups of patients 
undergoing surgeries for AAA and PAD. In the AAA group, we 
observed increase in vWF:CoR and tPA:antigen (Ag) levels, as 
well as a decrease in FVIII, antithrombin, and CD40L levels. There 
was no statistically significant difference between pre- and 
postoperative levels of D-dimer and PAP. In the PAD group, there 
was an increase in D-dimer and tPA levels and a decrease in FVIII, 
antithrombin, and CD40L levels. No perioperative differences in 
vWF and PAP levels were found.
There were no significant differences in the activity of 
antithrombin both preoperatively (89.8 vs. 92.1, P=0.52) and after 
surgery (71.1 vs. 75.8, P=0.34) between patients who received 
and those who did not receive heparin seven days prior to the 
procedure (Table 5).
Polok KJ, et al. - Vascular Surgery Influences Hemostasis
Table 1. Demographic and clinical characteristics of the study group.
Characteristics Study population (N = 38)
Demographics
Sex; N (%):
Males 31 (81.6%)
Females 7 (18.4%)
Age; mean (SD) 66.7 (7.6)
Reason for surgery
Abdominal aortic aneurysm; N (%) 16 (42.1%)
Peripheral artery disease; N (%) 22 (57.9%)
Clinical characteristics
Overweight; N (%) 20 (52.7%)
BMI*; mean (SD) 25.5 (4.3)
History of smoking; N (%) 33 (86.8%)
Packyears; median (quartiles) 40.5 (23.5-56)
Atrial fibrillation; N (%) 4 (10.5%)
Coronary artery disease; N (%) 15 (39.5%)
History of stroke/TIA†; N (%) 3 (7.9%)
Heart failure; N (%) 5 (13.2%)
Chronic obstructive pulmonary disease; N (%) 7 (18.4%)
Hypertension; N (%) 31 (81.6%)
Diabetes mellitus; N (%) 6 (15.8%)
Oral anticoagulants; N (%) 1 (2.6%)
Heparin < 7 days prior to surgery; N (%) 10 (26.3%)
Antiplatelet drugs < 7 days prior to surgery; N (%) 33 (86.8%)
BMI=body mass index; SD=standard deviation; †TIA=transient ischemic attack
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of antithrombin is associated with poorer patient outcomes. 
Interestingly, we did not observe any significant differences in 
pre- and postoperative antithrombin activity between patients 
who received and those who did not receive heparin within 
seven days before surgery.
Analysis of changes in the fibrinolytic system also presents 
a very complicated picture. We demonstrated a perioperative 
increase in D-dimer and tPA:Ag levels, but without any change 
between pre- and postoperative levels of PAP, which is a 
Table 2. Comparison of preoperative and postoperative levels of hemostatic, fibrinolytic, and inflammatory markers in the entire cohort.
Marker
Marker level (median and quartiles)
P value
Preoperative Postoperative
Factor VIII (%) 158.0(139.4 – 188.8)
103.3
(70.1 – 148.6) <0.001
vWF:CoR (%) 140.6(121.4 – 158.1)
162.8
(111.4 – 219.8) 0.17
Antithrombin (%) 92.1(86.9 – 100.1)
74.8
(69.3 – 84.9) <0.001
D-dimer (ng/ml) 938.0(697.0 – 3004.0)
2406.0
(1218.0 – 5237.0) 0.005
PAP* (ng/ml) 749.6(626.3 – 1089.8)
863.7
(621.7 – 1098.9) 0.21
tPA† (ng/ml) 10.1(8.7 – 14.1)
12.8
(10.3 – 16.4) 0.002
sCD40L‡ (pg/ml) 9092.9(7625.8 – 11363.6)
1249.6
(694.4 – 2827.1) <0.001
PAP=plasmin-antiplasmin complexes; ‡sCD40L=soluble cluster of differentiation 40 ligand; †tPA=tissue plasminogen activator; 
vWF:CoR=von Willebrand factor: ristocetin cofactor
Table 3. Comparison of preoperative and postoperative levels of hemostatic, fibrinolytic, and inflammatory markers in patients 
undergoing surgery for AAA.
Marker
Marker level (median and quartiles)
P value
Preoperative Postoperative
Factor VIII [%] 151.8(136.3 – 172.2)
132.6
(85.1 – 150.2) 0.04
vWF:CoR [%] 133.2(112.9 – 150.6)
200.0
(141.7 – 226.5) 0.001
Antithrombin [%] 92.1(89.3 – 97.7)
75.3
(71.7 – 80.7) <0.001
D-dimer [ng/ml] 3004.0(938.0 – 4800.0)
4164.0
(3102.5 – 6236.0) 0.14
PAP* [ng/ml] 745.0(608.0 – 1156.0)
964.2
(797.5 – 1109.2) 0.31
tPA† [ng/ml] 10.0(9.3 – 10.9)
11.7
(9.7 – 14.3) 0.02
sCD40L‡ [pg/ml] 8574.8(7625.8 – 9182.1)
1149.3
(676.7 – 1796.9) 0.001
AAA=abdominal aortic aneurysm; PAP=plasmin-antiplasmin complexes; ‡sCD40L=soluble cluster of differentiation 40 ligand; 
†tPA=tissue plasminogen activator; vWF:CoR=von Willebrand factor: ristocetin cofactor
Finally, we observed a significant decrease in the antithrombin 
activity which is probably a consequence of an intraoperative 
heparin administration. However, this decrease resulted in a 
postoperative antithrombin deficiency in more than 60% of 
the study population. This condition can expose patients to a 
higher risk of thrombotic events due to temporary depletion of 
this natural anticoagulant. It is worth mentioning that a study by 
Ranucci et al.[23] showed that a decrease in antithrombin levels 
after cardiac surgery procedures with lower postoperative levels 
Braz J Cardiovasc Surg 2019;34(3):327-34Polok KJ, et al. - Vascular Surgery Influences Hemostasis
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Table 4. Comparison of preoperative and postoperative levels of hemostatic, fibrinolytic, and inflammatory markers in patients 
undergoing surgery for PAD.
Marker
Marker level (median and quartiles)
P value
Preoperative Postoperative
Factor VIII [%] 174.1(151.9 – 201.8)
85.2
(48.7 – 148.6) <0.001
vWF:CoR [%] 143.1(135.2 – 167.3)
138.0
(102.1 – 177.7) 0.13
Antithrombin [%] 90.3(82.8 – 101.4)
71.4
(68.3 – 85.1) <0.001
D-dimer [ng/ml] 768.5(678.0 – 1302.0)
1539.5
(704.0 – 2902.0) 0.02
PAP* [ng/ml] 754.1(669.7 – 1089.8)
742.7
(578.3 – 1098.9) 0.81
tPA† [ng/ml] 10.5(6.7 – 17.7)
14.9
(12.1 – 18.4) 0.047
sCD40L‡ [pg/ml] 9549.7(7715.5 – 11918.0)
1943.5
(771.6 – 3442.6) <0.001
PAD=peripheral artery disease; PAP=plasmin-antiplasmin complexes; ‡sCD40L=soluble cluster of differentiation 40 ligand; 
†tPA=tissue plasminogen activator; vWF:CoR=von Willebrand factor: ristocetin cofactor
Fig. 1 – Impact of vascular procedures on markers’ levels. A) Factor VIII, P<0.001; B) 
von Willebrand factor:ristocetin factor (vWF:CoR), P=0.17; C) antithrombin, P<0.001; 
D) D-dimer, P=0.005; E) plasmin-antiplasmin complexes (PAP), P=0.21; F) tissue 
plasminogen activator (tPA), P=0.002; G) soluble cluster of differentiation 40 ligand 
(sCD40L), P<0.001.
A B C
D FE
G
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We decided to perform this pilot to obtain preliminary 
results and evaluate our methodology in order to optimally 
design the main study. First, credible assessment of changes 
in hemostatic and fibrinolytic activity and its association with 
potential postoperative complications requires larger and more 
homogenous study population. Moreover, in our opinion, the 
present and previous results suggest that the use of serum 
markers alone may be insufficient to reliably assess perioperative 
changes in hemostatic and fibrinolytic systems. Thus, the use 
of more up-to-date, dynamic methods, such as rotational 
thromboelastometry (ROTEM) or calibrated automated 
thrombography (CAT), should warrant more plausible results. 
ROTEM is an established method of real-time assessment of 
whole blood hemostasis. It encompasses several tests that give 
a unique opportunity to separately assess extrinsic pathway 
(EXTEM), intrinsic pathway (INTEM), to inhibit platelet function 
and therefore assess effectiveness of fibrin polymerization 
(FIBTEM), to exclude hyperfibrinolysis (APTEM), and to eliminate 
influence of heparin on blood coagulation (HEPTEM)[33].
CAT is another dynamic method useful in the evaluation 
of hemostatic and fibrinolytic systems’ activity, based on real-
time recording of thrombin generation[34]. Both tools would be 
particularly useful in patients undergoing vascular surgery who 
routinely receive heparin, anticoagulants, and blood products 
transfusions, which makes the assessment of hemostasis even 
more complex.
Limitation
Our study has several important limitations. First, the study 
group is relatively small and heterogeneous. Also, an association 
between perioperative changes in hemostatic and fibrinolytic 
markers and observed complications could not be thoroughly 
investigated due to a low number of events. Moreover, most of 
our patients experienced postoperative bleeding and received 
an antiplatelet drug or heparin prior to surgery which may have 
influenced some of the studied markers’ levels. Finally, employing 
intraoperative and additional postoperative measurements 
would markedly improve our understanding of perioperative 
alterations in hemostatic and fibrinolytic systems’ activities.
CONCLUSION
We demonstrated that major vascular surgeries lead to 
changes in both hemostatic and fibrinolytic activities, however 
marker of overall plasmin production. D-dimer is a biomarker 
of ongoing clot formation and fibrinolysis and an increase in its 
level is a sign of higher fibrinolytic activity. On the other hand, 
elevation of tPA:Ag levels is an indication of hypofibrinolytic 
state. Interestingly, according to some larger previous studies, 
higher levels of both tPA:Ag and D-dimer are associated with an 
increased risk of cardiovascular events[24].
Analysis of subgroups offered some further valuable insights. 
Firstly, there was an increase in vWF:CoR level in the AAA group 
that was not observed in PAD group, which might suggest more 
pronounced activation of coagulation system associated with 
open aortic repair compared to surgeries on peripheral arteries. 
Moreover, D-dimer levels increased perioperatively in patients 
undergoing surgery for PAD, while in the other group there 
was no statistically significant change in its level, which may 
represent stronger triggering of fibrinolysis associated with these 
procedures. However, an assessment of absolute values offers 
an important observation – D-dimer levels are four times higher 
preoperatively and more than two times higher postoperatively in 
patients in the AAA group than in the PAD group. This may indicate 
that hyperfibrinolysis is more pronounced in the AAA group, while 
it is the PAD surgery that significantly activates this pathway.
sCD40L is considered a proinflammatory and prothrombotic 
molecule. Its contribution to the development of atherosclerosis 
is strongly suggested and increased levels of sCD40L are 
associated with higher cardiovascular risk[25-28]. In current study, 
we observed a decrease in sCD40L level after both types of 
vascular procedures, which corroborates the study by Yip et 
al. showing similar change in sCD40L in patients undergoing 
coronary stenting. The authors hypothesized that it may either 
be a result of recovery from acute inflammation or be associated 
with reduced progression of inflammation in the plaque 
lesion[29]. This explanation can probably also be applied to our 
study. However, for the time being, clinical significance of this 
decrease in sCD40L level remains unclear.
There is a paucity of studies comparing preoperative and 
postoperative levels of hemostatic and fibrinolytic activation 
markers in patients undergoing vascular surgeries. Their results 
are difficult to compare due to heterogeneous methodologies, 
i.e., different markers and blood collection times. Nevertheless, 
these few published papers that we found suggest that 
surgical procedures change the activity of both hemostatic and 
fibrinolytic systems, although the direction of changes varies 
between the studies, especially among fibrinolytic markers[30-32].
Table 5. Comparison of pre- and postoperative levels of antithrombin between patients who received and did not receive heparin 
within seven days before the procedure.
Patients receiving heparin 
(N=10)
Patients not receiving heparin 
(N=28)
P value
Preoperative antithrombin activity; median (IQR) [%]
89.8
(83.8 – 98.8)
92.1
(87.4 – 99.6)
0.52
Postoperative antithrombin activity; median (IQR) [%]
71.1
(66.4 – 74.5)
75.8
(70.9 – 85.0)
0.34
IQR=interquartile range
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